Yahoo
NYSE American - Nasdaq Real Time Price USD

VolitionRx Limited (VNRX)

0.1917 +0.0099 (+5.45%)
As of 1:29:11 PM EDT. Market Open.
Chart Range Bar
Loading chart for VNRX
  • Previous Close 0.1818
  • Open 0.1843
  • Bid 0.1919 x 50000
  • Ask 0.1931 x 50000
  • Day's Range 0.1730 - 0.1944
  • 52 Week Range 0.1600 - 9.6000
  • Volume 712,324
  • Avg. Volume 8,684,384
  • Market Cap (intraday) 5.763M
  • Beta (5Y Monthly) 1.17
  • PE Ratio (TTM) --
  • EPS (TTM) -3.8000
  • Earnings Date (est.) Nov 12, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 13.62

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

volition.com

57

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/29/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

VNRX
96.31%
S&P 500 (^GSPC)
12.62%

1-Year Return

VNRX
97.77%
S&P 500 (^GSPC)
11.89%

3-Year Return

VNRX
98.82%
S&P 500 (^GSPC)
87.24%

5-Year Return

VNRX
99.71%
S&P 500 (^GSPC)
67.40%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 985.08k
Earnings -6.66M
Profit Margin -676.57%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-6M
-4M
-2M
0
-1400.0%
-1200.0%
-1000.0%
-800.0%

Analyst Insights

View More

Analyst Price Targets

2.00
13.62 Average
0.1917 Current
24.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/20/2026
Analyst D. Boral Capital
Rating Action Downgrade
Rating Hold
Price Action --
Price Target --

Statistics

View More

Valuation Measures

Annual
As of 10/28/2026
  • Market Cap

    5.47M

  • Enterprise Value

    12.71M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    0.51

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    5.17

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -142.94%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    2.46M

  • Net Income Avi to Common (ttm)

    -26.1M

  • Diluted EPS (ttm)

    -3.8000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.79M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -9.21M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

0.1917 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: